SEATTLE, Nov. 18, 2020 /PRNewswire/ — TwinStrand Biosciences today announced it has entered into a worldwide non-exclusive agreement to sublicense two foundational patent families to Foundation Medicine and its affiliates relating to TwinStrand Duplex Sequencing™ error-correction technology. Duplex Sequencing increases the accuracy of next-generation sequencing as much as 10,000 times, allowing the detection of ultra-low frequency mutations that would otherwise be hidden by technical noise inherent to the sequencing process.
“Staying at the forefront of innovative solutions to advance cancer care is central to our commitment to patients,” said Cindy Perettie, chief executive officer at Foundation Medicine. “We are excited to partner with TwinStrand to support doctors in making genomically-informed treatment decisions.”
“This agreement validates the strength of TwinStrand’s technology and intellectual property portfolio,” said Dr. Jesse Salk, chief executive officer at TwinStrand Biosciences. “We are pleased that Foundation Medicine has partnered with us to use our patented